VERAXA Biotech Announces Formation of Clinical Advisory Board to Support Expansion of Proprietary Pipeline in Oncology

HEIDELBERG, Germany, May 21, 2024 -- VERAXA Biotech GmbH, an emerging leader in designing novel cancer therapies, announced today the formation of a Clinical Advisory Board to provide medical and clinical strategic guidance to the Company as its proprietary pipeline matures further towards and through clinical development. The Company previously announced the in-licensing of a clinical-stage antibody therapy in acute myeloid leukemia and published more details regarding its ongoing platform technology strategy.

“Attracting such an esteemed group of KOLs from the field of oncology and with profound expertise across a range of highly impactful antibody-based therapies will add valuable support for VERAXA’s pipeline development strategy,” commented Christoph Antz, Ph.D., CEO and Co-Founder of VERAXA. “We look forward to working with these renowned experts as our product pipeline of innovative antibody-based programs continues to evolve and diversify.”

Prof. Dr. Ralf C. Bargou currently serves as the Director at the Comprehensive Cancer Center (CCC) Mainfranken and holds the Chair for Translational Oncology at the University Hospital Würzburg. He is a renowned expert for his significant contributions to immuno-oncology, particularly in the development of T-cell engaging bi-specific antibodies. His instrumental role in the creation of the bi-specific antibody blinatumomab earned him the Paul Martini Prize in 2009 and the Inventor of the Year Award in2016. He also developed targeted therapies for measurable residual disease (MRD) in acute lymphatic leukemia (ALL).

Dimitrios Tzachanis, MD, PhD, is a Professor of Medicine and the Clinical Director of the BMT Division at UC San Diego He specializes in treating patients with cancers of the blood and lymph system at the joint UC San Diego Health / Sharp HealthCare Blood and Marrow Transplantation Program with a focus on autologous and allogeneic stem cell transplantation and chimeric antigen receptor (CAR)T-cell therapy. He has published more than sixty peer-reviewed articles in medical journals such as the New England Journal of Medicine, the Lancet, Blood, Nature Immunology, among others.

Prof. Dr.med. Matthias Miederer is a renowned nuclear medicine physician leading the Department of Translational Imaging in Oncology at the National Center for Tumor Diseases (NCT/UCC), a joint center of excellence serving the University Hospital Dresden, the Medical Faculty at Dresden’s University of Technology, the German Cancer Research Centre DKFZ, and the Helmholtz-Association’s HDZR Center. In his role, Professor Miederer is paving the way for new radiopharmaceuticals into clinical practice in therapeutic and diagnostic applications. Prior to his current role, Professor Miederer worked at the University Medical Center of the University of Mainz, the Charité in Berlin, at the Klinikum rechts der Isar in Munich and as a Research Fellow at the Memorial Sloan Kettering Cancer Center.

Prof. Dr. Gernot Stuhler is entrepreneur and Adjunct Professor at University of Würzburg heading a research group focused on T cell-engaging antibody derivatives and exploring combinatorial immune-oncology strategies. In previous roles, he served as a senior physician at the Würzburg University Hospital and as Chief Physician at the German Clinic for Diagnostics (DKD) in Wiesbaden, Germany. Professor Stuhler was trained in Immunology at the Max-Planck-Institute for Biology and Immunogenetics in Tübingen, Germany and at the Dana Farber Cancer Institute, Harvard Medical School, in Boston, USA.

About VERAXA Biotech

At VERAXA Biotech, we strive to establish the premiere drug discovery and development engine for antibody drug conjugates and other novel antibody-based therapy concepts. Wielding a suite of transformative technology innovations and applying thorough quality-by-design principles in drug discovery, we are accelerating our pipeline of antibody drug conjugates and novel antibody formats into and through clinical development. VERAXA Biotech originates from scientific discoveries made at the European Molecular Biology Laboratory (EMBL), a world-leading institute for life science research and ground-breaking enabling technologies. For more information, please visit www.veraxa.com.

‍

Contact

VERAXA  Biotech GmbH

Dr. Christoph Antz

CEO

Telephone: +49-6221-3521330

Email: antz@veraxa.com

For  media

Mario Brkulj

Valency Communications

Telephone: +49 160 9352 9951

Email: mbrkulj@valencycomms.eu

‍